Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …

Simple Summary The treatment of peri-hilar (h-CCA) and intrahepatic (i-CCA)
cholangiocarcinoma is an evolving field in hepato-pancreato-biliary surgery. Continuous …

Background and Aim Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are
increasingly well characterized, but their impact on outcome and prognosis remains …

Simple Summary This review discusses multimodality treatment strategies for intrahepatic
cholangiocarcinoma (iCC). Surgical resection remains the only potentially curative …

Biliary tract cancers (BTCs) comprise a heterogenous group of aggressive and rare
malignancies arising in the bile duct outside or within the liver. BTCs include …

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy
and is increasing in incidence. Long-term outcomes are optimized when patients undergo …

Intrahepatic cholangiocarcinoma (iCCA) develops inside the liver, between bile ductules
and the second-order bile ducts. It is the second most frequent primary liver cancer after …

Background Recurrence rates of intrahepatic cholangiocarcinoma (iCCA) after curative
hepatectomy are as high as 50% to 70%, and about half of these recurrences occur within 2 …

Background Upfront surgery is the current standard for resectable intrahepatic
cholangiocarcinoma (ICC) despite high treatment failure with this approach. We sought to …

Simple Summary Perihilar cholangiocarcinoma is a rare disease with generally poor
outcomes. Complete surgical resection remains the only chance at long-term survival …